Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 21 | 2025 | 779 | 4.370 |
Why?
|
| Methotrexate | 13 | 2025 | 341 | 2.610 |
Why?
|
| Antimetabolites, Antineoplastic | 11 | 2025 | 181 | 2.070 |
Why?
|
| Leukemia | 3 | 2024 | 370 | 1.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 1237 | 1.400 |
Why?
|
| Lymphoma | 4 | 2024 | 323 | 1.220 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1135 | 1.190 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2020 | 66 | 1.000 |
Why?
|
| Allopurinol | 4 | 2023 | 71 | 0.990 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2022 | 13 | 0.780 |
Why?
|
| Vincristine | 2 | 2025 | 195 | 0.750 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2023 | 48 | 0.720 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 85 | 0.690 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1090 | 0.680 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 538 | 0.660 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 257 | 0.650 |
Why?
|
| Eosinophilia | 1 | 2020 | 101 | 0.630 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 116 | 0.610 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 356 | 0.600 |
Why?
|
| Furans | 1 | 2018 | 28 | 0.600 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 720 | 0.590 |
Why?
|
| Ketones | 1 | 2018 | 25 | 0.590 |
Why?
|
| Child | 27 | 2025 | 24454 | 0.590 |
Why?
|
| Salvage Therapy | 1 | 2019 | 194 | 0.590 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2017 | 10 | 0.580 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 236 | 0.580 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 60 | 0.540 |
Why?
|
| Neoplasms | 3 | 2025 | 2788 | 0.510 |
Why?
|
| Child, Preschool | 16 | 2025 | 14050 | 0.510 |
Why?
|
| Algorithms | 3 | 2025 | 1616 | 0.500 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 246 | 0.500 |
Why?
|
| Infant | 14 | 2025 | 12483 | 0.490 |
Why?
|
| Histiocytosis, Sinus | 1 | 2015 | 31 | 0.490 |
Why?
|
| Sirolimus | 2 | 2022 | 223 | 0.490 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 429 | 0.480 |
Why?
|
| Drug Monitoring | 3 | 2025 | 170 | 0.470 |
Why?
|
| Adolescent | 18 | 2025 | 19329 | 0.450 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 251 | 0.420 |
Why?
|
| Humans | 37 | 2025 | 124797 | 0.380 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 646 | 0.370 |
Why?
|
| Genotype | 1 | 2017 | 2557 | 0.360 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1664 | 0.360 |
Why?
|
| Mercaptopurine | 4 | 2022 | 71 | 0.350 |
Why?
|
| Azacitidine | 1 | 2010 | 53 | 0.340 |
Why?
|
| Nucleosides | 1 | 2009 | 17 | 0.340 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 64 | 0.320 |
Why?
|
| CpG Islands | 1 | 2010 | 323 | 0.310 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 158 | 0.310 |
Why?
|
| Male | 20 | 2025 | 61285 | 0.310 |
Why?
|
| Tissue Distribution | 2 | 2019 | 388 | 0.310 |
Why?
|
| Prognosis | 6 | 2025 | 4607 | 0.290 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 580 | 0.270 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1341 | 0.260 |
Why?
|
| Follow-Up Studies | 5 | 2025 | 5153 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 1691 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 1196 | 0.250 |
Why?
|
| Female | 19 | 2025 | 66555 | 0.250 |
Why?
|
| Cytarabine | 2 | 2022 | 98 | 0.240 |
Why?
|
| Maintenance Chemotherapy | 2 | 2023 | 20 | 0.240 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2024 | 28 | 0.240 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.240 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 321 | 0.230 |
Why?
|
| Constipation | 1 | 2024 | 115 | 0.220 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 121 | 0.220 |
Why?
|
| DNA Methylation | 1 | 2010 | 1004 | 0.220 |
Why?
|
| Thioguanine | 2 | 2022 | 21 | 0.210 |
Why?
|
| Young Adult | 6 | 2025 | 8987 | 0.200 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 23 | 0.200 |
Why?
|
| Spinal Cord Diseases | 1 | 2022 | 41 | 0.200 |
Why?
|
| Vidarabine | 1 | 2022 | 80 | 0.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 96 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 197 | 0.190 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 108 | 0.180 |
Why?
|
| Patient Selection | 1 | 2024 | 693 | 0.180 |
Why?
|
| Down Syndrome | 1 | 2023 | 198 | 0.170 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 52 | 0.170 |
Why?
|
| Phthalazines | 1 | 2019 | 13 | 0.170 |
Why?
|
| Antiemetics | 1 | 2017 | 22 | 0.140 |
Why?
|
| Morpholines | 1 | 2017 | 57 | 0.140 |
Why?
|
| Microtubules | 1 | 2018 | 197 | 0.140 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 37 | 0.140 |
Why?
|
| Hypoglycemia | 1 | 2018 | 194 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2024 | 16299 | 0.140 |
Why?
|
| Vomiting | 1 | 2017 | 107 | 0.140 |
Why?
|
| Unrelated Donors | 1 | 2016 | 82 | 0.130 |
Why?
|
| Adult | 5 | 2025 | 29472 | 0.130 |
Why?
|
| Lymphocyte Transfusion | 1 | 2016 | 57 | 0.130 |
Why?
|
| Survival Rate | 1 | 2019 | 2035 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 172 | 0.120 |
Why?
|
| Risk Factors | 2 | 2018 | 10272 | 0.110 |
Why?
|
| Bortezomib | 2 | 2024 | 73 | 0.100 |
Why?
|
| Mucositis | 2 | 2024 | 18 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 868 | 0.090 |
Why?
|
| Leukemia, T-Cell | 1 | 2009 | 11 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2025 | 549 | 0.080 |
Why?
|
| Splenic Neoplasms | 1 | 2009 | 11 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 44 | 0.080 |
Why?
|
| United States | 1 | 2024 | 10886 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2010 | 238 | 0.080 |
Why?
|
| Remission Induction | 1 | 2009 | 301 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 158 | 0.080 |
Why?
|
| Neutropenia | 2 | 2024 | 200 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2018 | 6137 | 0.070 |
Why?
|
| Costa Rica | 1 | 2025 | 13 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2011 | 12342 | 0.060 |
Why?
|
| Liposomes | 1 | 2025 | 170 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8182 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1708 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2022 | 32 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3341 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 1674 | 0.050 |
Why?
|
| Etoposide | 1 | 2022 | 117 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 155 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 390 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2010 | 4783 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 339 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2022 | 404 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 421 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 428 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 143 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 1319 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 295 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 320 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2017 | 126 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 192 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 731 | 0.030 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 15 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 35 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 21 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 17 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 50 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 113 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 41 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2013 | 71 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 376 | 0.030 |
Why?
|
| Recurrence | 1 | 2016 | 1425 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 632 | 0.020 |
Why?
|